Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.52 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.52 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.52 |
| ▸ | NAMPT | P43490 | 2/20 | 0.50 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27400423 | 0.83 | ALDH1A1 (0.55) | SMN1; SMN2MAPK10NAMPTKMT2AMEN1 | |
| SCHEMBL8594732 | 0.83 | CD274 (0.71) | NAMPTCD274TSHRKMT2AALDH1A1 | |
| SCHEMBL13007739 | 0.82 | SMN1; SMN2 (0.53) | SMN1; SMN2NAMPTKMT2AMEN1CYP2C19 | |
| SCHEMBL4748590 | 0.81 | CYP2D6 (0.65) | CYP2D6SMN1; SMN2MAPK8MAPK10TSHR | |
| SCHEMBL3090173 | 0.81 | TSHR (0.59) | SMN1; SMN2NAMPTCD274TSHRKMT2A | |
| SCHEMBL12298707 | 0.79 | SMN1; SMN2 (0.50) | SMN1; SMN2NAMPTKMT2AMEN1CYP2C19 | |
| SCHEMBL14070483 | 0.78 | ALDH1A1 (0.70) | CYP2D6SMN1; SMN2MAPK8MAPK10HTT | |
| SCHEMBL2507542 | 0.77 | NAMPT (0.60) | NAMPTKMT2AMEN1HDAC1 | |
| SCHEMBL22291745 | 0.77 | EPHX2 (0.64) | NAMPTKMT2AMEN1HDAC1 | |
| SCHEMBL3180689 | 0.76 | L3MBTL1 (0.61) | NAMPTTSHRNPSR1HDAC1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080293711-A1 | Chemokine receptor modulators | METASTATIX, INC. | 2008-11-27 | — | — | US | disclosed |
| US-20080293711-A1 | Chemokine receptor modulators | METASTATIX, INC. | 2008-11-27 | — | — | US | disclosed |
| US-20080293711-A1 | Chemokine receptor modulators | METASTATIX, INC. | 2008-11-27 | — | — | US | disclosed |
| WO-2008112156-A1 | CHEMOKINE RECEPTOR MODULATORS | ALTIRIS THERAPEUTICS (US) | 2008-09-18 | — | — | WO | disclosed |
| WO-2008112156-A1 | CHEMOKINE RECEPTOR MODULATORS | ALTIRIS THERAPEUTICS (US) | 2008-09-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080293711-A1 | Chemokine receptor modulators | CCR5, CCL2, CXCR4 | CYP2D6 2999/4885SMN1; SMN2 4829/4885MAPK8 919/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.